MedTrace Logo

OptiMized REsistaNt Starch in Inflammatory Bowel Disease: The MEND Trial

NCT04520594 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-01-29

No results posted yet for this study

Summary

The purpose of the study is to determine if a plant-based resistant starch that is optimized for the individual will target the underlying cause of inflammatory bowel disease and restore a "healthier" gut microbiome in pediatric participants with inflammatory bowel disease.

Conditions

Interventions

OTHER

Resistant Starch

7.5 g resistant starch/m2 oral consumption

OTHER

Placebo

Placebo oral consumption of food-grade cornstarch

Sponsors & Collaborators

  • Children's Hospital of Eastern Ontario

    lead OTHER

Principal Investigators

  • David Mack, MD, FRCPC · Children's Hospital of Eastern Ontario

  • Alain Stintzi, PhD · University of Ottawa

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-03
Primary Completion
2024-11-05
Completion
2026-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04520594 on ClinicalTrials.gov